Appraisal of risks from nonoccupational exposure to chlorpyrifos
- PMID: 11846640
- DOI: 10.1006/rtph.2001.1512
Appraisal of risks from nonoccupational exposure to chlorpyrifos
Abstract
The toxicological database for chlorpyrifos indicates that humans are not more sensitive than laboratory animals to the toxic effects. Although an oral dose of 1 mg/kg-day resulted in measurable levels of chlorpyrifos in the blood, daily dosing at this level from 9 days to 2 years did not affect brain acetylcholinesterase activity (AChE) in laboratory animals. Developmental toxicity did not occur at doses below maternal toxicity. Most nonoccupational illnesses resulting from entry into areas treated with chlorpyrifos likely stem from odor, rather than the ability of the organophosphate to inhibit AChE. Based on biological monitoring studies, chronic aggregate nonoccupational exposures to chlorpyrifos ranged from 0.0002 mg/kg-day (adults) to 0.0005 mg/kg-day (infants and small children)-1 order of magnitude less than exposures estimated by standard procedures. Other biological monitoring data indicated that cumulative exposure to all organophosphate pesticides ranged from 0.0003 mg/kg-day (adults) to 0.003 mg/kg-day (children). Considering all these factors, the risks of aggregate, nonoccupational exposure to chlorpyrifos have been overstated by more than a 1000-fold.
© 2002 Elsevier Science (USA).
Similar articles
-
Comparison of the in vitro sensitivity of rat acetylcholinesterase to chlorpyrifos-oxon: what do tissue IC50 values represent?Toxicol Appl Pharmacol. 1998 Jan;148(1):46-9. doi: 10.1006/taap.1997.8287. Toxicol Appl Pharmacol. 1998. PMID: 9465262
-
Comparison of the role of esterases in the differential age-related sensitivity to chlorpyrifos and methamidophos.Neurotoxicology. 2000 Feb-Apr;21(1-2):49-56. Neurotoxicology. 2000. PMID: 10794384
-
Kinetic analysis of the in vitro inhibition, aging, and reactivation of brain acetylcholinesterase from rat and channel catfish by paraoxon and chlorpyrifos-oxon.Toxicol Appl Pharmacol. 1996 Aug;139(2):365-73. doi: 10.1006/taap.1996.0177. Toxicol Appl Pharmacol. 1996. PMID: 8806854
-
Determination of the reference dose for chlorpyrifos: proceedings of an expert panel.J Toxicol Environ Health B Crit Rev. 1999 Jul-Sep;2(3):211-55. doi: 10.1080/109374099281179. J Toxicol Environ Health B Crit Rev. 1999. PMID: 10429680 Review.
-
Human red blood cell acetylcholinesterase inhibition as the appropriate and conservative surrogate endpoint for establishing chlorpyrifos reference dose.Regul Toxicol Pharmacol. 1999 Feb;29(1):15-22. doi: 10.1006/rtph.1998.1256. Regul Toxicol Pharmacol. 1999. PMID: 10051415 Review.
Cited by
-
Investigation of in vitro effects of ethephon and chlorpyrifos, either alone or in combination, on rat intestinal muscle contraction.Interdiscip Toxicol. 2010 Mar;3(1):35-9. doi: 10.2478/v10102-010-0002-6. Epub 2010 Mar 29. Interdiscip Toxicol. 2010. PMID: 21217869 Free PMC article.
-
GLUT1 deficiency syndrome as a cause of encephalopathy that includes cognitive disability, treatment-resistant infantile epilepsy and a complex movement disorder.Eur J Med Genet. 2012 May;55(5):332-4. doi: 10.1016/j.ejmg.2011.11.009. Epub 2011 Dec 20. Eur J Med Genet. 2012. PMID: 22212417 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources